PortalPublikationenSecondary leukemia after first-line high-dose chemotherapy f...

Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer

Standard

Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer. / Wierecky, J; Kollmannsberger, C; Boehlke, I; Kuczyk, M; Schleicher, J; Schleucher, N; Metzner, B; Kanz, L; Hartmann, J T; Bokemeyer, C.

in: J CANCER RES CLIN, Jahrgang 131, Nr. 4, 04.2005, S. 255-60.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Wierecky, J, Kollmannsberger, C, Boehlke, I, Kuczyk, M, Schleicher, J, Schleucher, N, Metzner, B, Kanz, L, Hartmann, JT & Bokemeyer, C 2005, 'Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer', J CANCER RES CLIN, Jg. 131, Nr. 4, S. 255-60. https://doi.org/10.1007/s00432-004-0628-x

APA

Wierecky, J., Kollmannsberger, C., Boehlke, I., Kuczyk, M., Schleicher, J., Schleucher, N., Metzner, B., Kanz, L., Hartmann, J. T., & Bokemeyer, C. (2005). Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer. J CANCER RES CLIN, 131(4), 255-60. https://doi.org/10.1007/s00432-004-0628-x

Vancouver

Wierecky J, Kollmannsberger C, Boehlke I, Kuczyk M, Schleicher J, Schleucher N et al. Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer. J CANCER RES CLIN. 2005 Apr;131(4):255-60. https://doi.org/10.1007/s00432-004-0628-x

Bibtex

@article{2863b4955a724faaaa7e990f132451a0,
title = "Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer",
abstract = "PURPOSE: We investigated the incidence of secondary leukemia in patients treated with first-line high-dose chemotherapy (HDCT) plus autologous stem cell transplantation (PBSCT) for advanced testicular cancer.METHODS: Three hundred and twenty-three patients who were entered into two consecutive prospective Phase-II studies of the German Testicular Cancer Study Group were analyzed. A total of 221 patients had received HD-VIP containing cisplatin, ifosfamide, and etoposide and 102 patients were treated with Tax-HD-VIP containing cisplatin, ifosfamide, etoposide, and paclitaxel, each cycle supported by autologous PBSCT.RESULTS: Patients had received a median cumulative etoposide dose of 4.9 g/m(2) (range, 2.2-9.4 g/m(2)). The median follow-up duration for all patients was 36 months (range, 0-128) with a median follow up time of 50 months (range, 0-128) for patients surviving at least 1 year after therapy. One patient developed a secondary acute myeloid leukemia (s-AML) involving a chromosomal translocation t(11;19)(q23;p13.3) 24 months after the start of chemotherapy resulting in a cumulative incidence of 0.48% [95% confidence interval (CI) 0-1.42]. Additionally, two patients with primary mediastinal germ cell cancer developed a myelodysplastic syndrome. No solid tumors had occurred.CONCLUSIONS: HDCT including high-dose etoposide with autologous PBSCT as first-line therapy for advanced testicular cancer was associated with an acceptably low risk of developing secondary leukemia.",
keywords = "Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Clinical Trials, Phase II as Topic, Etoposide, Follow-Up Studies, Germany, Germinoma, Humans, Ifosfamide, Leukemia, Myeloid, Acute, Male, Mediastinal Neoplasms, Multicenter Studies as Topic, Myelodysplastic Syndromes, Neoplasms, Second Primary, Paclitaxel, Peripheral Blood Stem Cell Transplantation, Testicular Neoplasms, Translocation, Genetic, Transplantation, Autologous",
author = "J Wierecky and C Kollmannsberger and I Boehlke and M Kuczyk and J Schleicher and N Schleucher and B Metzner and L Kanz and Hartmann, {J T} and C Bokemeyer",
year = "2005",
month = apr,
doi = "10.1007/s00432-004-0628-x",
language = "English",
volume = "131",
pages = "255--60",
journal = "J CANCER RES CLIN",
issn = "0171-5216",
publisher = "Springer",
number = "4",

}

RIS

TY - JOUR

T1 - Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer

AU - Wierecky, J

AU - Kollmannsberger, C

AU - Boehlke, I

AU - Kuczyk, M

AU - Schleicher, J

AU - Schleucher, N

AU - Metzner, B

AU - Kanz, L

AU - Hartmann, J T

AU - Bokemeyer, C

PY - 2005/4

Y1 - 2005/4

N2 - PURPOSE: We investigated the incidence of secondary leukemia in patients treated with first-line high-dose chemotherapy (HDCT) plus autologous stem cell transplantation (PBSCT) for advanced testicular cancer.METHODS: Three hundred and twenty-three patients who were entered into two consecutive prospective Phase-II studies of the German Testicular Cancer Study Group were analyzed. A total of 221 patients had received HD-VIP containing cisplatin, ifosfamide, and etoposide and 102 patients were treated with Tax-HD-VIP containing cisplatin, ifosfamide, etoposide, and paclitaxel, each cycle supported by autologous PBSCT.RESULTS: Patients had received a median cumulative etoposide dose of 4.9 g/m(2) (range, 2.2-9.4 g/m(2)). The median follow-up duration for all patients was 36 months (range, 0-128) with a median follow up time of 50 months (range, 0-128) for patients surviving at least 1 year after therapy. One patient developed a secondary acute myeloid leukemia (s-AML) involving a chromosomal translocation t(11;19)(q23;p13.3) 24 months after the start of chemotherapy resulting in a cumulative incidence of 0.48% [95% confidence interval (CI) 0-1.42]. Additionally, two patients with primary mediastinal germ cell cancer developed a myelodysplastic syndrome. No solid tumors had occurred.CONCLUSIONS: HDCT including high-dose etoposide with autologous PBSCT as first-line therapy for advanced testicular cancer was associated with an acceptably low risk of developing secondary leukemia.

AB - PURPOSE: We investigated the incidence of secondary leukemia in patients treated with first-line high-dose chemotherapy (HDCT) plus autologous stem cell transplantation (PBSCT) for advanced testicular cancer.METHODS: Three hundred and twenty-three patients who were entered into two consecutive prospective Phase-II studies of the German Testicular Cancer Study Group were analyzed. A total of 221 patients had received HD-VIP containing cisplatin, ifosfamide, and etoposide and 102 patients were treated with Tax-HD-VIP containing cisplatin, ifosfamide, etoposide, and paclitaxel, each cycle supported by autologous PBSCT.RESULTS: Patients had received a median cumulative etoposide dose of 4.9 g/m(2) (range, 2.2-9.4 g/m(2)). The median follow-up duration for all patients was 36 months (range, 0-128) with a median follow up time of 50 months (range, 0-128) for patients surviving at least 1 year after therapy. One patient developed a secondary acute myeloid leukemia (s-AML) involving a chromosomal translocation t(11;19)(q23;p13.3) 24 months after the start of chemotherapy resulting in a cumulative incidence of 0.48% [95% confidence interval (CI) 0-1.42]. Additionally, two patients with primary mediastinal germ cell cancer developed a myelodysplastic syndrome. No solid tumors had occurred.CONCLUSIONS: HDCT including high-dose etoposide with autologous PBSCT as first-line therapy for advanced testicular cancer was associated with an acceptably low risk of developing secondary leukemia.

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Cisplatin

KW - Clinical Trials, Phase II as Topic

KW - Etoposide

KW - Follow-Up Studies

KW - Germany

KW - Germinoma

KW - Humans

KW - Ifosfamide

KW - Leukemia, Myeloid, Acute

KW - Male

KW - Mediastinal Neoplasms

KW - Multicenter Studies as Topic

KW - Myelodysplastic Syndromes

KW - Neoplasms, Second Primary

KW - Paclitaxel

KW - Peripheral Blood Stem Cell Transplantation

KW - Testicular Neoplasms

KW - Translocation, Genetic

KW - Transplantation, Autologous

U2 - 10.1007/s00432-004-0628-x

DO - 10.1007/s00432-004-0628-x

M3 - SCORING: Journal article

C2 - 15627215

VL - 131

SP - 255

EP - 260

JO - J CANCER RES CLIN

JF - J CANCER RES CLIN

SN - 0171-5216

IS - 4

ER -